We're exiting our position in this chipmaker and right-sizing another winner

Jim Cramer's Charitable Trust is exiting its remaining 120 Broadcom shares at about $326 each, realizing an average gain of roughly 128% on shares bought in 2023 and 2024. It is also selling 85 CrowdStrike shares at about $251, reducing the position to 665 shares and portfolio weighting from 4.8% to 4.25%, while realizing an estimated 187% gain on those shares. The Broadcom sale reflects a defensive response to data-center funding concerns and uncertainty around Anthropic's expected IPO and Meta's future equity raises; the CrowdStrike sale is described as position-sizing, not a negative view of its fundamentals.

Analysis

The portfolio action is a weak sentiment signal, not evidence of deteriorating company fundamentals or meaningful market-wide selling pressure. The more important mechanism is financing: if hyperscalers or AI labs face higher costs or less access to capital, they may defer data-center buildouts before cancelling them. That would pressure timing and visibility for Broadcom’s AI-related networking and custom-silicon demand, while potentially leaving long-term AI adoption intact. Watch order commentary and hyperscaler capex plans rather than treating an IPO or equity raise as a direct demand signal.

CrowdStrike’s trim is explicitly position sizing; it offers no new read-through on customer demand. Its subscription model may be less directly exposed to data-center funding cycles, but this article does not establish it as a hedge. Micron could benefit if memory demand remains firm, though the proposed rotation from AI infrastructure into memory is not yet supported by fresh operating data.

Contrarian risk: the funding narrative may overstate the chance of cancelled projects and understate the ability of large technology companies to fund strategic infrastructure internally. Conversely, even without cancellations, a slower pace of commitments could compress AI-supply-chain multiples over the next 1–3 months. Over 6–18 months, actual capex and supplier order trends matter more than IPO timing. No trade is warranted from this single portfolio manager’s sale alone.

Key Decisions for Investors

• Do not treat the AVGO sale as a standalone short signal. For existing AI-infrastructure exposure, consider a measured beta hedge rather than adding outright shorts; reassess after hyperscaler capex updates and Broadcom order commentary.
• Keep CRWD separate from the AI-funding thesis: the disclosed reduction was portfolio sizing, not a fundamental downgrade. Avoid inferring a cybersecurity-sector signal.
• Track whether Meta’s financing plans or the Anthropic IPO change actual infrastructure commitments. A sustained reduction in capex guidance or supplier orders would strengthen the bearish thesis; continued spending and stable order visibility would falsify it.
• Treat MU as a watch item, not an automatic rotation target. Verify memory pricing, inventory, and forward demand before expressing the relative-value idea; weaker pricing or guidance would argue against it.